Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 13/20 | 0.43 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.38 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9882350 | 0.93 | PIM1 (0.52) | PIM1PRKD1PRKD2PTPN11PRKCQ | |
| SCHEMBL9882361 | 0.91 | PIM1 (0.47) | PIM1PRKD1PRKD2PTPN11 | |
| SCHEMBL9882338 | 0.91 | PIM1 (0.51) | PIM1PRKD1PRKD2PTPN11MAPT | |
| SCHEMBL9882054 | 0.83 | PIM1 (0.49) | PIM1PRKD1PRKD2 | |
| SCHEMBL9882040 | 0.82 | PRKD1 (0.53) | PIM1PRKD1PRKD2PRKCQ | |
| SCHEMBL9882301 | 0.80 | PRKCQ (0.44) | PIM1PTPN11PRKCQMAPT | |
| SCHEMBL9882349 | 0.79 | PRKCQ (0.40) | PIM1PRKD1PRKD2PRKCQ | |
| SCHEMBL9882001 | 0.78 | PRKCQ (0.57) | PRKCQ | |
| SCHEMBL9882282 | 0.77 | PRKCQ (0.60) | PIM1PRKD1PRKD2PRKCQ | |
| SCHEMBL9882316 | 0.77 | PRKCQ (0.44) | PIM1PRKCQMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193722-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193722-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-24 | — | — | US | disclosed |
| US-20130252939-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252939-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-26 | — | — | US | disclosed |
| US-20120136000-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-05-31 | — | — | US | disclosed |
| US-20120136000-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252939-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | MAP3K20, MAP3K5, PRKACA | PIM1 305/4885PRKD1 96/4885PRKD2 76/4885 |
| US-20120136000-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | MAP3K20, MAP3K5, PRKACA | PIM1 305/4885PRKD1 96/4885PRKD2 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.